MRGPRX2 and non-small cell lung carcinoma: Our findings may have relevance to TKI-induced DHRs mediated by MRGPRX2, future studies are warranted to characterize other TKIs such as crizotinib, which is used to treat metastatic non-small cell lung cancer.